U.S. markets closed

Isracann Biosciences Inc. (ISCNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0458+0.0026 (+6.02%)
At close: 03:16PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0432
BidN/A x N/A
AskN/A x N/A
Day's Range0.0425 - 0.0550
52 Week Range0.0250 - 0.2330
Avg. Volume206,675
Market Cap6.836M
Beta (5Y Monthly)-0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.1270
Earnings DateApr 27, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ISCNF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Market Update: COST, TGNA, ITRI, LLY, ANTM, WWW, AGNC, GNRC, LTHM, NRZStocks rallied on Friday morning, paring some of their recent sharp losses. However, the major indices were still on track for their sixth straight weekly decline amid continued concerns about inflation and the Fed's ability to control it. In an NPR interview on Thursday, Fed Chair Jerome Powell reiterated that the central bank would likely raise interest rates by 50 basis points at each of its next two meetings, but that it was 'prepared to do more' if the data warranted. The Dow rose 1.4%, the S&P 2.1%, and the Nasdaq 3.6%. Crude oil rose $4 to $110 per barrel, while gold traded near $1813 per ounce.
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • GlobeNewswire

    Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada

    VANCOUVER, British Columbia, May 19, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations. Praesidio Health ( is a Canadian medical re

  • GlobeNewswire

    Isracann Biosciences Renews Leadership to Meet Changing Demands

    VANCOUVER, British Columbia, April 15, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately. As Isracann moves from development to operations, and to better accommodate the integration of natural health medicine (“NHM”) research and development to mee

  • GlobeNewswire

    Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers

    VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news releases dated February 23, 2022 and March 28, 2022, it has closed its acquisition of Praesidio Health Inc. (“Praesidio”). Pursuant to the definitive agreement dated March 24, 2022 with Praesidio and the shareholders of Praesidio (the “Praesidio Shareholders”), the Company acquired all of the i